Investor presentation, 18 December 2023
Released
Released
Announcement PDF
NNZ-2591
Phelan-McDermid syndrome
Phase 2 trial top-line results
18 December 2023
IMPROVING THE LIVES OF PEOPLE WITH
NEURODEVELOPMENTAL DISABILITIES
Page□
1
Forward looking statements
This presentation contains forward looking statements that involve
risks and uncertainties. Although we believe that the expectations
reflected in the forward looking statements are reasonable at this
time, Neuren can give no assurance that these expectations will
prove to be correct. Actual results could differ materially from those
anticipated. Reasons may include risks associated with drug
development and manufacture, risks inherent in the regulatory
processes, delays in clinical trials, risks associated with patent
protection, future capital needs or other general risks or factors.
2
Phelan-McDermid syndrome has overwhelming unmet medical need
Cause of the syndrome
Deletion or variation in the
SHANK3 gene on
chromosome 22
Broad and severe impact on life
Intellectual impairment
Behavioural issues
Sleep disorders
Seizures (~40% of patients)
Language deficits
Feeding difficulties
Motor delays
Low muscle tone
SHANK3 protein plays a
role in the formation,
maintenance and function
of dendrites and synapses
Sweat less, risk of overheating
High pain tolerance
Difficulties toilet training
(~3/4 of patients)
GI dysfunction (most commonly
constipation)
Walking abnormalities
Frequent hospitalization and
heightened risk of accidents
From Voice of the Patient Report
Externally-Led Patient-Focused Drug
Development Meeting 8 Nov 2022
“PMS has an overwhelming unmet
medical need. There are no FDA approved
treatments for PMS despite its severely debilitating
manifestations. Parents and caregivers are open to
trying almost anything to try to relieve their child’s
suffering; most have tried an incredibly high
number of treatments and approaches for
symptom management, with very little success.
Some received medications that caused more
harm than good”
“PMS has severe quality of life impacts
on those living with the disease, as well
as on parents and siblings. Most activities
of daily life, including communicating needs or
wants, self-care (bathing, dressing, toileting) and
socializing with peers/siblings are affected. Most
individuals living with PMS rely on their parents
and caregivers for all their daily needs, and many
require 24-hour care.”
3
Consistent efficacy and clear dose response for NNZ-2591 in shank3 model
Memory
Learning
Sociability
Daily living
Daily living
Repetitive behavior
(pg/ml)
Anxiety
pERK
Motor function
length (m)
In biochemical testing, NNZ-2591 was shown to
normalize the abnormal length of dendritic spines
that form the synapse, the excess activated ERK
protein (pERK) and the depressed level of IGF-1 in
shank3 knockout mice
Incidence of audiogenic seizures
WT + vehicle
KO + vehicle
KO + x mg/kg
KO + 2x mg/kg
KO + 4x mg/kg
KO + 8x mg/kg
0%
60%
50%
30%
10%
10%
Abnormal dendrites in
shank3 knockout mice
cells in culture
Normalization after
treatment with NNZ-2591
4
Phase 2 Clinical Trial Results Highlights
•
NNZ-2591 was safe and well tolerated, with no clinically significant changes in laboratory
values or other safety parameters during treatment
•
Significant improvement was assessed by both clinicians and caregivers across multiple
efficacy measures
•
Improvements were consistently seen across clinically important aspects of Phelan-McDermid
syndrome, including communication, behaviour, cognition/learning and socialisation
•
Clinician and caregiver global efficacy measures showed a level of improvement typically
considered clinically meaningful:
•
•
Clinical Global Impression of Improvement (CGI-I) – mean score of 2.4 with 16 out of 18 children
showing improvement assessed by clinicians
•
Caregiver Overall Impression of Change (CIC) – mean score of 2.7 with 15 out of 18 children showing
improvement assessed by caregivers
For 10 out of 14 efficacy endpoints, improvement from baseline on overall/total scores was
statistically significant (p<0.05)1
1 Wilcoxon signed rank test
5
Phase 2 Clinical
Trial Design
6
Neuren’s Phase 2 trial in children with Phelan-McDermid syndrome
First study in pediatric patients, collecting the data needed to design a registration study
4 US sites: Rush University, Massachusetts General Hospital, Boston Children’s Hospital and Texas Children’s Hospital
n subjects:
Up to 20
Age range:
3 to 12
Week 0
•
•
Primary endpoints are
safety, tolerability and PK
Global
•
CGI-I
•
Caregiver
Impression of
Change (CIC)
Secondary endpoints include
14 efficacy measurements
A key objective is selection
of the best primary efficacy
endpoint or endpoints for a
registration study
•
Symptom Specific Communication
•
CGI-S
GI Health
GIHQ
PMS
Clinician
Domain
Specific
Rating
Scale
Caregiver
Top 3
Concerns
Week 19
Week 17
Week 10
•
•
Follow-up
Up-titration to
12 mg/kg BID
Week 4
Endpoints
•
NNZ-2591 treatment
Screening
/Baseline
•
MB-CDI
•
ORCA
Quality of Life
•
QI-Disability
•
ICND
Sleep
•
CSHQ
Behaviour
•
Aberrant
Behavior
Checklist-2
•
Behavior
Problems
Inventory
•
Vineland
Adaptive
Behavior
Scales
7
Participant disposition
23 participants
18 dosed1
5 screen failures
15 completers
3 discontinued (none
related to study drug)
1 All 18 subjects contributed to safety and efficacy data
8
Dosed participant demographics
Age
Mean
8.6 yrs
Median
8.3 yrs
Min - Max
4.4 – 13.0 yrs
Sex
Cognitive level (non-verbal IQ/DQ)
Female
6 (33%)
<50
13 (72%)
Male
12 (67%)
Missing
NVIQ
1 (6%)
>=50
4 (22%)
9
Safety and
Tolerability
10
Safety and tolerability summary
NNZ-2591 was safe and well tolerated
✓ Well tolerated
✓ Most Treatment Emergent Adverse Events (TEAE) were mild to moderate
•
1 Serious TEAE (gastroenteritis) not related to study drug, occurred during safety follow-up period after end of
treatment
•
3 discontinuations due to TEAEs not related to study drug: 2 due to testing positive for COVID-19 and 1 due to
seizures
✓ No clinically significant changes in laboratory values, electrocardiogram (ECG) or other safety parameters were
observed during treatment
11
TEAEs in 2 or more subjects
Event
NNZ-2591 (N=18)
n (%)
Event
NNZ-2591 (N=18)
n (%)
Constipation
2 (11.1)
Somnolence
3 (16.7)
Diarrhea
2 (11.1)
Pyrexia
3 (16.7)
Nausea
2 (11.1)
Fatigue
2 (11.1)
Vomiting
2 (11.1)
Aggression
2 (11.1)
COVID-19
3 (16.7)
Insomnia
2 (11.1)
Nasopharyngitis
2 (11.1)
Decreased Appetite
3 (16.7)
Otitis Media
2 (11.1)
Rhinorrhea
2 (11.1)
Psychomotor Hyperactivity
4 (22.2)
12
Efficacy
13
Efficacy endpoints summary
Efficacy measures and p-values1 (Total/Overall scores)
Behaviour
Global
•
Statistically significant
improvement vs baseline in
10/14 efficacy
endpoints
•
•
CGI-I 2.4
Mean
of
and Median of 2.0 with
p-value <0.0001
CIC 2.7
Mean
of
and Median of 3.0 with
p-value =0.0003
CGI-I
<0.0001
CIC
0.0003
CGI-S
0.0156
GI Health
GIHQ total frequency
0.0013
Aberrant Behavior
Checklist-2 total
0.0013
Behavior Problems
Inventory total frequency
0.0326
Vineland Adaptive Behavior
Scales Composite
0.1710
Symptom Specific
Quality of Life
QL InventoryDisability total
0.0066
PMS Clinician Domain
Specific Rating Scale total
Impact of Childhood
Neurologic Disability
0.1094
Caregiver Top 3 Concerns
total
0.0156
0.0005
Communication
Sleep
CSHQ total
1 Wilcoxon signed rank test
0.0191
MB-CDI Total Vocabulary
0.0647
ORCA T-Score
0.0714
14
Best practice implemented for CGI-I and CIC measures in PMS
•
Both CGI-I and CIC scores
reflect overall improvement
from baseline
1 – Very Much Improved
Clinical Global Impression of
Improvement (CGI-I)
Caregiver Impression of
Change (CIC)
Scoring
Clinician gives an overall score
and domain scores
Caregiver gives an overall
score and domain scores
Also identifies the one symptom
area that has most influenced
his or her rating of the child’s
overall function
Domain
Anchors
•
Expressive Communication
•
Communication
•
Receptive Communication
•
Social interaction
•
Gross Motor Function
•
Behavior
•
Fine Motor Function
•
Motor abilities
•
Social Interaction
•
Seizures
•
Cognition and Learning
•
•
Self-Care
Cognitive abilities/ability to
learn
•
Self-care skills
•
GI problems
•
Sensory sensitivities
2 – Much Improved
3 – Minimally Improved
4 – No Change
5 – Minimally Worse
6 – Much Worse
7 – Very Much Worse
•
All clinician raters complete
training to calibrate scoring and
interpretation of the scoring
anchors amongst raters.
Training was done at study
start up and a follow-up
calibration training was done
during the study
15
CGI-I (clinician) results by subject and by domain
Mean CGI-I score of 2.4 with 16 out of 18 children showing improvement
Improvement
16
CIC (caregiver) results by subject and by domain
Mean CIC score of 2.7 with 15 out of 18 children showing improvement
Improvement
17
Clinical Global Impression of Severity (CGI-S) and Caregiver Top 3
Concerns results by domain
7 subjects improved by one point on the overall CGI-S score after 13 weeks of treatment and
improvement was observed in the most common concerns of caregivers (communication,
behaviour, social interaction, self-care)
CGI-S domains
Caregiver Top 3 Concerns
(Domains based on frequency of nomination)
Improvement
Improvement
18
Quality of Life Inventory-Disability results by subject and by subscale
Improvement
Improvement
19
Aberrant Behavior Checklist-2 results by subject and by subscale
Improvement
Improvement
Subjects with a score of zero not shown
20
Child Sleep Habits Questionnaire results by subject and by subscale
Improvement
Improvement
Subjects with a score of zero not shown
21
Gastrointestinal Health Questionnaire results by subject and by subscale
Improvement
Improvement
Acknowledgment: GIHQ developed by Kathleen J. Motil, MD, PhD, Baylor College of Medicine
22
ORCA T-Score and MB-CDI Total Vocabulary results by subject
Improvements in communication observed in ORCA T-Score and MB-CDI Total Vocabulary, as
well as domains/subscales in CGI-I, CGI-S, CIC and Caregiver Top 3 Concerns
ORCA T-Score
Improvement
MB-CDI Total Vocabulary
Improvement
23
Testimonials
24
Clinician and caregiver testimonials
Clinicians
Caregivers
“Marked improvement in expressive language and moderate
improvement in socialization.”
“Using more words while retaining eye contact… Improved
pretend play… Initiating eye contact”
“Teachers noted improvement in learning new skills.”
“Less scripting, less stimming… More flexible with changes…
In general, they are more safe-even at bus stop”
“Able to focus work at school, both to the things they always
enjoy and new tasks.”
“Expressive communication- significant improvement in using
more complex phrases, better back and forth
communication. Better expressing needs. Some commentary
on how mom is feeling, "I want you to be happy".”
“Expressive communication- babbling much more than
baseline.”
“More focused , engaged, aware of their environment,
people.”
“So much happier, not throwing self to ground when can’t
get his way”
“More attentive and it makes for an easy learner, Now can
focus better on what we are trying to teach.”
“A few 1-2 word phrases that were not at baseline “oh boy”,
“Hi Mama”, “I love you”, “oh my”.”
“Attention span is great right now… He can focus long
enough to complete tasks and try new things.”
“Gross motor- Stronger climbing ladders, comes downstairs
which never did before, Walks upstairs without help (needed
help at baseline).”
“Can now run instead of walking fast… Good balance, not
needing assistance on stairs.”
25
PMS
opportunity
26
PMS is historically under-diagnosed, but this is changing
Estimated prevalence is 1% of people with autism - 1/8,000 to 1/15,000 males and females1
Potential PMS patients
US
Europe
Japan
China
Other2
17,000 – 32,0003
21,000 – 41,0003
5,000 - 9,0003
51,000 – 95,0003
16,000 - 31,0003
Phelan-McDermid Syndrome
Foundation members
2,937
Currently
3,216 1,739 US
members
3,106
2,688
2,394
2,108
1,735
1,437
1,239
75% of PMS
patients have been
diagnosed with an
ASD
~1% of autism
patients have
SHANK3 mutations
1,002
2014
Opportunity to accelerate diagnosis
2017
2020
2023
•
Rising awareness
•
EL-PFDD meeting
with FDA in 2022
•
ICD code assigned in
2023
•
Enhanced genetic
testing technologies
•
Expanding ADDM
network sites
Autism
US ADDM tracks
440k children with
autism spectrum
disorder
1 Phelan McDermid Syndrome Foundation (PMSF) (www.pmsf.org)
2 Brazil, Israel, South Korea, Australia and New Zealand
3 Estimates based on United Nations population data 2022, derived by applying the estimated prevalence range to the populations under 60 years (urban population only for China)
27
Neuren is leading development of a first approved treatment for PMS
Phase 2 Program Status
•
Orphan Drug designation in
US and EU
•
Phase 2 clinical
development in the US
under an IND
•
Eligible for Rare Pediatric
Disease Designation
Priority Review Voucher
program
Limited products in development
Company
Neuren engaging with all
stakeholders
Product Development Stage
Phase 2 (successful)
#2
Phase 2 trial (closed Jan 2021)
#3
Phase 1
#4
Pre-clinical
#5
Pre-clinical
Leading clinicians
28
NNZ-2591 in development for multiple neurodevelopmental disorders
Potential patients
Disorder
Gene mutation
Published prevalence estimates
US1
Europe1
RoW1, 2
PhelanMcDermid
SHANK3
1/8,000 to 1/15,000 males and females
24,000
31,000
103,500
Pitt Hopkins
TCF4
1/34,000 to 1/41,000 males and females
6,000
8,000
28,000
Angelman
UBE3A
1/12,000 to 1/24,000 males and females
16,000
20,000
66,000
Prader-Willi
15q11-q13
1/10,000 to 1/30,000 males and females
17,000
21,000
72,000
63,000
80,000
270,000
•
The mechanism of action of NNZ-2591 is relevant for many other neurodevelopmental synaptopathies
•
Top-line results from Pitt Hopkins syndrome Phase 2 trial expected in Q2 2024
1 Estimates derived by applying the mid-point of the prevalence estimate range to the populations under 60 years
2 RoW comprises Japan, China (urban population), Brazil, Israel, South Korea, Australia and New Zealand
29
CONTACT
Jon Pilcher, CEO
jpilcher@neurenpharma.com
+61 438 422 271
30
Phelan McDermid syndrome affects all genders and ages
% currently diagnosed patients by
gender1
% currently diagnosed patients by age group1
34%
36%
29%
48%
17%
52%
15% 16%
13%
12%
9%
5%
5%
5%
4%
1%
Male
Female
< 12 m
1-2 yrs
3-4 yrs 5-10 yrs 11-20 yrs21-30 yrs31-40 yrs41-60 yrs
Patients current age
60+
When first diagnosed
1 Estimates based on survey of participants in the Externally-Led Patient Focused Drug Development (EL-PFDD) meeting on Phelan-McDermid Syndrome 8 Nov 2022
31
Consistent efficacy in Pitt Hopkins, Angelman and Prader-Willi models
Hypoactivity & anxiety
Daily living
Sociability
Daily living
Motor
Cognition
Angelman
Hypoactivity
Daily living
Learning & Memory
Sociability
Repetitive behavior
Motor performance
Pitt
Hopkins
Obesity
Circulating IGF-1
levels
Cognition
Hypoactivity
Hypoactivity
Daily living
Social preference
Social interaction
Anxiety
PraderWilli
32
Novel mechanisms of action – NNZ-2591
Reversible binding
regulates
bioavailability
IGF-1
Produce
essential
growth factor
Activates PI3K-AktmTOR and Ras-MAPKERK signaling pathways
in neurons, regulating
formation of new
synapses
IGF-1
receptor
on cell
surface
•
NNZ-2591 is a synthetic analog
of cyclic glycine proline, a
peptide that occurs naturally in
the brain, designed to be more
stable, orally bioavailable and
readily cross the blood-brain
barrier
•
NNZ-2591 can regulate the
amount of IGF-1 that is
available to activate IGF-1
receptors
•
The effects of NNZ-2591 are
“state-dependent” – correcting
impairment, but not impacting
normal cells
IGF
Binding
Protein‐3
Competitively binds to
binding protein,
regulating IGF-1
binding1
NNZ-2591
1 doi: 10.1038/srep04388: Guan et al, 2017: Cyclic glycine-proline (cGP) regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1
33
Share your feedback
Discover